How AI is supercharging drug development

AI is accelerating drug development by reducing preclinical costs and timelines by up to 70%, according to a TD Cowen survey of biopharma leaders. The technology is driving demand for advanced software and computational tools to simulate biological processes and predict drug interactions, though no AI-discovered drug has yet received FDA approval.